Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes MCIT/TCET) Transitional Coverage for Emerging Technologies (TCET)/MCIT Policies promoting medical innovation Heart Valve Disease Awareness AI in Healthcare FDA Reauthorization/FDA User Fees Diversity in Clinical Trials Coverage with Evidence Development
2026 · 2nd Quarter (Apr 1 - June 30)
EDWARDS LIFESCIENCES LLC
Filed by EDWARDS LIFESCIENCES, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 20, 2026
- Income
- Not reported
- Expenses
- $280,000.00
- Registrant
- EDWARDS LIFESCIENCES, LLC
- Client
- EDWARDS LIFESCIENCES LLC
- Filing UUID
- 6130dd6e-30ec-4616-aedb-f1780d958944
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
CMS Coverage Policies For Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes MCIT/TCET) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Coverage with Evidence Development
Tariffs
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.